Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines
- PMID: 39728847
- PMCID: PMC11679773
- DOI: 10.3390/pharmacy12060182
Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines
Abstract
Background: Valproates are recognized for their significant teratogenic risks, which can lead to physical defects and developmental disorders when used during pregnancy. To mitigate these risks, the Pregnancy Prevention Program (PPP) was developed by European regulators for patients and healthcare professionals (HCPs). Despite the crucial nature of this program, the implementation of the PPP does not appear to be fully effective. This situation highlights the need for a deeper understanding of HCPs' knowledge, attitudes, and behaviors regarding the PPP.
Methods: A cross-sectional study using anonymous electronic questionnaires was conducted. The questionnaires were developed by a board of experts from eight different EU countries and were distributed among prescribers (general practitioners (GPs), neurologists, and psychiatrists) and pharmacists. Descriptive statistics were used to analyze the obtained data on participants' knowledge, attitudes, and behaviors regarding the prescribing and dispensing of valproate-containing medicines to women of reproductive age, as well as the impact of PPP materials on their work.
Results: The study results indicate that while HCPs in Latvia are generally aware of valproate teratogenic risks, significant gaps remain in the implementation of the PPP. A considerable number of both prescribers and pharmacists expressed the belief that they are not responsible for educating patients about the PPP, attributing this responsibility to other specialists. Furthermore, barriers such as a lack of time and accessible materials were identified.
Conclusions: The roles and responsibilities of HCPs should be clearly defined to improve adherence to the PPP. Further research is needed to assess prescription and dispensing strategies, as well as HCPs' attitudes toward the PPP. Additionally, re-evaluating and enhancing the accessibility of PPP materials is essential in effective risk management and better patient care.
Keywords: Pregnancy Prevention Program; healthcare professionals; survey; valproates.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
The Awareness and Adherence of the Valproate Pregnancy Prevention Program: A Questionnaire Survey among Healthcare Professionals, Pharmacists, and Patients in Denmark.Int J Environ Res Public Health. 2023 Jan 26;20(3):2215. doi: 10.3390/ijerph20032215. Int J Environ Res Public Health. 2023. PMID: 36767582 Free PMC article.
-
Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross-Sectional Survey in Six European Countries.Pharmacoepidemiol Drug Saf. 2024 Nov;33(11):e70046. doi: 10.1002/pds.70046. Pharmacoepidemiol Drug Saf. 2024. PMID: 39532540
-
Awareness, knowledge and practice of healthcare professionals following implementation of a Pregnancy Prevention Program for sodium valproate in Ireland: a multi-stakeholder cross-sectional study.Expert Opin Drug Saf. 2021 Aug;20(8):965-977. doi: 10.1080/14740338.2021.1933429. Epub 2021 Aug 23. Expert Opin Drug Saf. 2021. PMID: 34080507
-
Personal barriers to addressing intimate partner abuse: a qualitative meta-synthesis of healthcare practitioners' experiences.BMC Health Serv Res. 2021 Jun 9;21(1):567. doi: 10.1186/s12913-021-06582-2. BMC Health Serv Res. 2021. PMID: 34107941 Free PMC article. Review.
-
Healthcare Professionals' Knowledge, Attitudes, and Practices in the Assessment, and Management of Sickle-Cell Disease: A Meta-Aggregative Review.Diseases. 2024 Jul 14;12(7):156. doi: 10.3390/diseases12070156. Diseases. 2024. PMID: 39057127 Free PMC article. Review.
References
-
- European Medicines Agency PRAC Recommends New Measures to Avoid Valproate Exposure in Pregnancy. [(accessed on 13 September 2024)]. Available online: https://www.ema.europa.eu/en/news/prac-recommends-new-measures-avoid-val....
-
- European Medicines Agency Valproate and Related Substances—Referral. [(accessed on 13 September 2024)]. Available online: https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related....
-
- Rutkovska I., Seilis A., Neikena Z., Poplavska E. Impact of Risk Minimisation Measures on Valproate Use among Women of Reproductive Age in Latvia Between 2013 and 2020: A 7-Year Nationwide Prescription Database Study. Drugs Real World Outcomes. 2023;10:639–649. doi: 10.1007/s40801-023-00394-y. - DOI - PMC - PubMed
-
- National Health Service List of Reimbursed Medicines. [(accessed on 13 September 2024)]; Available online: https://www.vmnvd.gov.lv/lv/kompensejamo-zalu-saraksti.
-
- State Medicines Agency Vēstule Veselības Aprūpes Speciālistiem. Valproāts: Jauni Lietošanas Ierobežojumi; Jāievieš Grūtniecības Nepieļaušanas Programma. [(accessed on 13 September 2024)]; Available online: https://www.zva.gov.lv/lv/jaunumi-un-publikacijas/jaunumi/vestule-veseli....
LinkOut - more resources
Full Text Sources